Plenary Session
Session 1 – Optimising Outcomes for Patients With Cardio-Renal-Metabolic (CRM) Disease
Chairs – Andrew Coats and Manisha Sahay
-
The Urgency and Rationale of Addressing CRM in Our Patients – Brendon Neuen
-
The Role of Primary Care – Ana Cebrián Cuenca
-
Staging CKM Disease – Merlin Thomas
-
The Role of Imaging – Victoria Delgado
-
Panel Discussion
Meet the Experts
Earlier is Better: The Benefits of Timely Diagnosis and Intervention in CKM Syndrome
Cardiovascular-kidney-metabolic Syndrome: The Critical Importance of Early Diagnosis – Carol Pollock
Screening for Heart Failure in Patient with Diabetes: Insights from TARTAN-HF – Mark Petrie
Supported by unrestricted educational grant funding from AstraZeneca
Plenary Session
Session 2 – Evolving Guidelines in CKM
Chairs – Christoph Wanner and Gianluigi Savarese
Integrated Care: The Rationale for Simpler, Unified Guidelines – Joao Ferreira
Standards of Care in Diabetes 2026: Chronic Kidney Disease and Risk Management – Sylvia Rosas
KDIGO Update: New Perspectives in Kidney Health – Christoph Wanner
iCardio Guidelines: Global Cascade Guidelines on Obesity and HF – Vijay Chopra
Assessing Metabolic Disorders: The EAS Perspective – Stefano Romeo
Panel Discussion
Keynote Session
Kidney Disease and Heart Failure: Recent Advances and Current Challenges
Nisha Bansal
Meet the Experts
Implementation of Evidence-based Therapies for CKM Conditions: How to Move Forward?
Implementation of Evidence-based Therapies for Cardiovascular Kidney-metabolic Conditions – Are we on Track? – Stephen Greene
Translating Knowledge into Practice – How can Implementation Science Help? – Christoph Wanner
Supported by unrestricted educational grant funding from AstraZeneca
Plenary Session
Session 3 – Foundational (and Almost Foundational) Therapies in CRM
Chairs – Antonio Ceriello and Nisha Bansal
-
SGLT2 Inhibitors – Nisha Bansal
-
MRAs?! – Maja Cikes
-
GLP1 RA?! – Naveed Sattar
-
ASI – Shahzeb Khan
-
Panel Discussion
Meet the Experts
A New Weapon for an Old Target: Aldosterone Synthase Inhibition in Cardiovascular & Kidney Disease
Targeting Aldosterone in Cardiovasular and Kidney Disease: The Therapeutic Potential of Aldosterone Synthase Inhibitors – David Cherney
Benefits of Aldosterone Synthase Inhibitors in Patients with Cardiorenal Disease: Current Clinical Evidence – Javed Butler
Supported by an unrestricted educational grant from Boehringer Ingelheim
Plenary Session
Session 4 – Anti-Obesity Medication (AOMs) Clinical Experience
Chairs – Marc-André Cornier and James Burton
-
The Nephrologist View – Michel Jadoul
-
The Diabetologist View – Jennifer Green
-
The Cardiologist View – Javed Butler
-
Muscle-Wasting Associated With AOMs – Stefan Anker
-
Panel Discussion
Meet the Experts
Targeting Mineralocorticoid Receptor Overactivation Across the CKM Continuum: From Landmark Trials to Integrated Clinical Practice
From Trial Evidence to Clinical Decision: What the Finerenone Programme Means for your CKD Patients – Amy Mottl
The Polytherapy Challenge: How to Sequence and Combine Finerenone in Real-World CKM Practice – Muthiah Vaduganathan
Supported by an unrestricted educational grant from Bayer
Plenary Session
Session 5 – Non-Steroidal MRAs
Chairs – Nisha Bansal and Muthiah Vaduganathan
Non-Steroidal vs. Steroidal MRAs – What Clinicians Need to Know – Gerasimos Filippatos
Expanding the Spectrum: Finerenone in Heart Failure Across CKM Risk Profiles – Justin Ezekowitz
Finerenone in CKD: Expanding the Spectrum from Type 2 Diabetes to Type 1 Diabetes – Hiddo Heerspink
Finerenone in CKD: Expanding the Spectrum from Type 2 Diabetes to Non-diabetic CKD – Hiddo Heerspink
Panel Discussion
Meet the Experts
Replay of 'Earlier is Better: The Benefits of Timely Diagnosis and Intervention in CKM Syndrome'
Supported by unrestricted educational grant funding from AstraZeneca
Plenary Session
Session 6 – Improving Outcomes in HFpEF: New Frontiers
Chairs – Pedro Schwartzmann and Clara Saldarriaga
What is HFpEF? – John McMurray
Obesity is HFpEF & HFpEF is Obesity?! – Milton Packer
Diagnostic Challenges: Identifying HFpEF in Clinical Practice – Cristina Gavina
Management Strategies: Current and Emerging Therapies – Sheldon Litwin
Panel Discussion
Plenary Session
Session 7 – Obesity as a Central Player in CRM
Chairs – Carel Le Roux and Carol Pollock
Clinical Frameworks: Recent Definitions and Evolving Classifications of Obesity – Ritwika Mallik
The Kidney and Obesity: Mechanisms of Renal Injury – Peter Rossing
Type 2 Diabetes and Obesity – Antonio Ceriello
Sarcopenic Obesity – Stephan von Haehling
Panel Discussion
Meet the Experts
Replay of 'Targeting Mineralocorticoid Receptor Overactivation Across the CKM Continuum: From Landmark Trials to Integrated Clinical Practice'
Supported by an unrestricted educational grant from Bayer
Plenary Session
Session 8 – Managing Key Parameters in CRM
Chairs – Shahzeb Khan and Ahmed Bennis
Potassium Levels – Patrick Rossignol
Albuminaria – David Wheeler
NT ProBNPs – Evangelos Giannitsis
Low eGFR – James Burton
Low Sodium – Julio Núñez
Lipids – Pierre François Sabouret
Panel Discussion
Meet the Experts
Replay of 'A New Weapon for an Old Target: Aldosterone Synthase Inhibition in Cardiovascular & Kidney Disease'
Supported by an unrestricted educational grant from Boehringer Ingelheim
Plenary Session
Session 9 – Combination Therapies for CKM
Chairs – Giuseppe Rosano and Muthiah Vaduganathan
Synergistic Effects: Combination Therapy With Finerenone and Empagliflozin – Jennifer Green
SGLT2 Inhibitors and Combination Therapies – Shahzeb Khan
The Polypill: Can Simplification Change the Treatment Landscape? – Piotr Ponikowski
Combining Incretins With Muscle Anabolics – Stefan Anker
Panel Discussion
Meet the Experts
Don’t Overlook the Liver! Advances in the Management of Metabolic Dysfunction-associated Steatohepatitis (MASH)
Don't Overlook the Liver! MASH and the Cardiovascular-kidney-liver-metabolic Syndrome – Sven Francque
Current and Emerging Treatments for MASH and Associated Conditions – Antonio Ceriello
Supported by an unrestricted educational grant from Boehringer Ingelheim
Plenary Session
Session 10 – From Prevention to Shared Decision-Making
Chairs – Fausto Pinto and Anu Lala-Trindade
-
Cardiometabolic Health in the Course of Women’s Life – Glaucia Moraes de Oliveira
-
Implementation Science in the Path Toward Pharmacoequity – Dinushika Mohottige
-
The LATTICE Initiative – Ankeet Bhatt
-
Panel Discussion
Christoph Wanner
Course Director
University Hospital Wuerzburg, Wuerzburg, DE
Shelley Zieroth
Course Director
University of Manitoba, Winnipeg, CA
Stefan Anker
Charité Campus Virchow-Klinikum, Berlin, DE
Nisha Bansal
University of Washington, Seattle, US
Ahmed Bennis
Ibn Rochd University Hospital, Casablanca, MA
Ankeet Bhatt
Kaiser Permanente San Francisco Medical Center, San Francisco, US
Barry Borlaug
Mayo Clinic and Foundation, Rochester, US
James Burton
University of Leicester, Leicester, UK
Javed Butler
University of Mississippi Medical Center, Jackson, US
Ana Maria Cebrián Cuenca
Centro de Salud San Antón, Murcia, ES
Antonio Ceriello
IRCCS MultiMedica, Milan, IT
David Cherney
University of Toronto, Toronto, CA
Vijay Chopra
Max Super Speciality Hospital, New Delhi, IN
Maja Cikes
University Hospital Centre Zagreb, Zagreb, HR
Andrew Coats
Monash University, Melbourne, AU
Marc-Andre Cornier
Medical University of South Carolina, Charleston, US
Victoria Delgado
Germans Trias i Pujol Hospital, Barcelona, ES
Justin Ezekowitz
University of Alberta, Edmonton, CA
Joao Ferreira
University of Porto, Porto, PT
Gerasimos Filippatos
National and Kapodistrian University of Athens, Athens, GR
Sven Francque
Antwerp University Hospital, Edegem, BE
Cristina Gavina
University of Porto, Porto, PT
Evangelos Giannitsis
University Hospital Heidelberg, Heidelberg, DE
Jennifer Green
Duke Clinical Research Institute, Durham, US
Stephen Greene
Duke Clinical Research Institute, North Carolina, US
Hiddo J L Heerspink
University Medical Center Groningen, Groningen, NL
Michel Jadoul
Université catholique de Louvain, Louvain-la-Neuve, BE
Shahzeb Khan
Baylor Scott & White Health, Dallas, US
Anu Lala-Trindade
The Mount Sinai Hospital, New York, US
Carel Le Roux
University College Dublin, Dublin, IE
Sheldon Litwin
Medical University of South Carolina, Charleston, US
Ritwika Mallik
Barts Health NHS Trust, London, UK
John McMurray
University of Glasgow, Glasgow, UK
Dinushika Mohottige
Icahn School of Medicine at Mount Sinai, New York, US
Glaucia Moraes de Oliveira
Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, BR
Amy Mottl
UNC School of Medicine, North Carolina, US
Brendon Neuen
The George Institute for Global Health, Sydney, AU
Julio Núñez
Instituto de Investigacion Sanitaria INCLIVA, Valencia, ES
Milton Packer
Baylor University Medical Center, Texas, US
Mark Petrie
University of Glasgow, Glasgow, UK
Fausto Pinto
Santa Maria Hospital - CHULN, Lisbon, PT
Carol Pollock
The University of Sydney, Camperdown, AU
Piotr Ponikowski
Wrocław Medical University, Wrocław, PL
Stefano Romeo
University of Gothenburg, Gothenburg, SE
Giuseppe Rosano
St Georges Medical School, London, UK
Sylvia Rosas
Joslin Diabetes Center, Boston, US
Patrick Rossignol
CHRU de Nancy, Nancy, FR
Peter Rossing
Steno Diabetes Center Copenhagen, Herlev, DK
Pierre François Sabouret
Pitie Salpetriere APHP University Hospital, Paris, FR
Manisha Sahay
Osmania General Hospital, Hyderabad, IN
Clara Inés Saldarriaga
University of Antioquia, Medellín, CO
Naveed Sattar
University of Glasgow, Glasgow, UK
Gianluigi Savarese
Karolinska Institute, Stockholm, SE
Pedro Schwartzmann
Hospital Unimed, Ribeirao Preto, BR
Merlin Thomas
Monash University, Melbourne, AU
Muthiah Vaduganathan
Brigham and Women's Hospital, Massachusetts, US
Stephan von Haehling
University Medical Centre of Gottingen, Goettingen, DE
David Wheeler
University College London, London, UK
